Otsuka will pay $700 million to Transcend shareholders at closing, with an additional $525 million in contingent payments tied to future sales milestones
The LIFT-PD study will enroll 75 Parkinson’s patients experiencing apathy across 16 sites in Germany, Bulgaria, Poland and Spain
ADQUEY’s approval opens the door to a new alternative for millions of Americans struggling with atopic dermatitis
The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe
The multicenter study will enroll 75 patients across 16 sites in Germany, Bulgaria, Poland, and Spain
Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor
Tolvaptan Tablets are indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
Tolvaptan is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Rexulti Tablets
Tolvaptan Tablets (RLD Jynarque) had estimated annual sales of USD 287 million in the U.S. (IQVIA MAT August 2023)
Subscribe To Our Newsletter & Stay Updated
